Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a lab notebook. Tenaya Therapeutics’ disclosures dive deep into AAV capsid engineering, clinical trial design, and cash runway assumptions—details that matter when therapies aim to cure inherited cardiomyopathies. If you have ever searched, “Tenaya Therapeutics SEC filings explained simply” or wondered how a single 8-K might impact dilution risk, you know the challenge.
Stock Titan solves it. Our AI parses every Tenaya Therapeutics annual report 10-K simplified, flags pipeline milestones in each 10-Q, and delivers real-time alerts the moment a Tenaya Therapeutics Form 4 insider transactions real-time notice hits EDGAR. You will see at a glance who bought shares, how R&D spend shifted, and what FDA feedback appeared in the latest 8-K material events explained. Need the numbers fast? The platform auto-builds tables that compare quarter-over-quarter trial expenses and manufacturing capital needs—no more hunting through footnotes.
Use cases professionals rely on daily include:
- Monitoring Tenaya Therapeutics executive stock transactions Form 4 ahead of material data readouts
- Reviewing a Tenaya Therapeutics quarterly earnings report 10-Q filing for cash-burn trends
- Extracting pay packages from a Tenaya Therapeutics proxy statement executive compensation section
- Running a Tenaya Therapeutics earnings report filing analysis to benchmark pipeline progress
With comprehensive coverage of every filing type—10-K, 10-Q, 8-K, S-3, and more—plus AI-powered summaries that translate scientific jargon into plain language, understanding Tenaya Therapeutics SEC documents with AI becomes straightforward. Stay current, save hours, and make informed decisions with data that updates the instant Tenaya Therapeutics insider trading Form 4 transactions are filed.
Tenaya Therapeutics is raising capital by offering 50,000,000 units in an underwritten public stock and warrant sale. Each unit is priced at $1.20 and includes one share of common stock and one five-year warrant to buy a share at $1.50, with underwriters purchasing at $1.128 per unit. The transaction is expected to generate approximately $60 million in gross proceeds and is scheduled to close on December 15, 2025, subject to customary conditions.
The warrants can be exercised for cash, or on a cashless basis if no effective registration statement covers the underlying shares, and adjust for stock splits and similar events. Exercises are limited so that, after giving effect to an exercise, a holder (together with its affiliates) cannot exceed 4.99% or, if elected, 9.99% of Tenaya’s outstanding common stock or combined voting power, with the percentage adjustable, upon at least 61 days’ notice, to a level not above 19.99%. The company, its officers and directors, and certain shareholders have agreed to a 60-day lock-up, and the deal is being conducted under an already effective shelf registration statement.
Tenaya Therapeutics is offering 50,000,000 units in an underwritten public sale, each unit consisting of one share of common stock and a five-year warrant to purchase one share at an exercise price of $1.50. The units are priced at $1.20, for gross proceeds of
The company’s common stock trades on the Nasdaq Global Select Market under the symbol TNYA, while the Warrants will not be listed and have ownership caps of 4.99% or 9.99%, adjustable up to 19.99% with notice. Net proceeds, together with existing cash and investments, will fund ongoing and planned development of lead gene therapy candidates TN‑201 and TN‑401 and other pipeline work, plus working capital and general corporate purposes. As of September 30, 2025, Tenaya had 163,744,535 shares of common stock outstanding, so investors in this deal will experience immediate dilution, including an estimated
Tenaya Therapeutics, Inc. (TNYA)
After this transaction, the reporting person beneficially owns 93,971 shares of Tenaya Therapeutics common stock. This total includes 50,470 shares that will be issued upon the vesting of restricted stock units in the future.
Tenaya Therapeutics, Inc. reported an insider transaction by its Chief Medical Officer. On 11/17/2025, the officer sold 2,877 shares of Tenaya common stock at $1.33 per share. The sale was made to cover tax withholding obligations related to the vesting of restricted stock units that were originally granted on January 24, 2025.
After this transaction, the officer beneficially owned 169,926 shares of Tenaya common stock, including 85,838 shares that will be issued upon the vesting of restricted stock units. The filing is a routine Form 4 disclosure of insider equity activity.
Tenaya Therapeutics, Inc. reported a routine insider transaction by its Chief Executive Officer, who is also a director. On 11/17/2025, the reporting person sold 3,126 shares of Tenaya Therapeutics common stock at a price of $1.33 per share. According to the filing, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units originally awarded on February 6, 2025.
After this tax-related sale, the reporting person beneficially owned a total of 299,666 shares of Tenaya Therapeutics common stock. This total includes 211,275 shares that will be issued upon the future vesting of restricted stock units. The filing indicates that the ownership is held directly by the reporting person.
Tenaya Therapeutics (TNYA) reported Q3 2025 results. Net loss was $20.3 million, improving from $25.6 million a year ago, as operating expenses fell to $20.9 million from $26.7 million. Research and development declined to $15.4 million and general and administrative to $5.6 million. Interest income was $0.7 million.
Cash and cash equivalents were $56.3 million, with total assets of $105.0 million and stockholders’ equity of $82.9 million as of September 30, 2025. For the nine months, net loss was $70.4 million versus $87.3 million in 2024. The company completed a March 2025 follow‑on offering with net proceeds of approximately $48.8 million and raised $0.9 million via at‑the‑market sales in January. An SVB loan agreement provides the right to draw $10.0 million through December 31, 2025, with up to an additional $20.0 million at the lender’s discretion.
Programs advanced with interim TN‑201 data presented in November; the FDA placed MyPEAK‑1 on clinical hold to standardize monitoring and immunosuppression protocol activities. Tenaya recognized $1.5 million from an $8.0 million CIRM grant for TN‑401 and recorded $1.2 million related to a 2025 workforce reduction. The company believes existing resources, potential loan availability, and recent warrant exercises will fund operations for at least twelve months following filing. Shares outstanding were 166,505,885 as of November 4, 2025.
Tenaya Therapeutics furnished an 8-K under Item 2.02 to announce its financial results for the quarter ended September 30, 2025.
The company attached the full earnings press release as Exhibit 99.1 and noted that the information in Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act.
Tenaya Therapeutics announced that the FDA placed a clinical hold on MyPEAK-1, its Phase 1b/2a trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy. The agency requested a protocol amendment primarily to standardize patient monitoring and management of the immunosuppression regimen across trial sites.
The request followed proactive correspondence about future plans for TN-201 and draws on data reviewed by the independent DSMB in summer 2025, which concluded TN-201 had an acceptable safety profile to allow enrollment at 3E13 vg/kg and 6E13 vg/kg. TN-201 has been generally well tolerated, and there have been no new meaningful safety events since that review.
Tenaya is working with the FDA to resolve the hold and intends to resume dosing once protocol changes are implemented at trial sites. The company does not expect this action to impact data milestones or development timelines for TN-201.
Tomohiro Higa, Senior Vice President, Finance of Tenaya Therapeutics, Inc. (TNYA), reported three share dispositions on 08/18/2025 to cover tax withholding related to vested restricted stock units. The filings show sales of 523, 717, and 1,722 shares at a weighted average sales price of $1.253 (individual sale prices ranged from $1.18 to $1.32).
The report lists the reporting person’s beneficial ownership after each sale as 97,777, 97,060, and 95,338 shares respectively, and discloses that the totals include restricted stock units scheduled to vest: 60,844, 58,907, and 54,220 shares. The form was signed by an attorney-in-fact, Jennifer Drimmer Rokovich, on 08/18/2025. No other transactions or derivative holdings are reported in this filing.
Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics, Inc. (TNYA), reported three separate sales on 08/18/2025 to cover tax withholding for vested restricted stock units. Each sale was executed at a weighted average price of $1.253, with individual trade prices ranging from $1.18 to $1.32. The filings show dispositions of 1,608; 1,608; and 1,837 shares, leaving the reporting person with 176,248; 174,640; and 172,803 shares respectively after each transaction. The filing discloses remaining unvested RSUs that will result in future issuance: 103,132; 98,757; and 93,757 shares referenced in the explanatory footnotes. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Tenaya Therapeutics (TNYA)?
What is the market cap of Tenaya Therapeutics (TNYA)?
